Richard Beckman - Mar 1, 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Medical Officer
Signature: Richard Beckman, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: ADVM
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/3/2023, 04:23 PM
Previous filing: Sep 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+225K		$0.00	225K	Mar 1, 2023	Common Stock	225K	$0.75	Direct	F1

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of March 1, 2023 (the "Vesting Commencement Date"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Content

Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of March 1, 2023 (the "Vesting Commencement Date"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.